Amyotrophic Lateral Sclerosis (ALS) Pipeline

DelveInsight’s, “Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight, 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

Amyotrophic Lateral Sclerosis (ALS) Understanding

Amyotrophic Lateral Sclerosis (ALS) Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare, progressive neurodegenerative disorder that affects the nerve cells responsible for controlling voluntary muscle movement. It belongs to a broader category of conditions called motor neuron diseases, characterized by the gradual degeneration and death of motor neurons. These neurons normally transmit signals from the brain to the spinal cord and muscles, enabling voluntary muscle activity. In ALS, both upper motor neurons in the brain and lower motor neurons in the spinal cord deteriorate, disrupting communication with muscles. As a result, muscles progressively weaken, twitch (fasciculations), and undergo wasting (atrophy), leading to loss of voluntary movement. Although the exact cause remains unclear, research suggests that a combination of genetic and environmental factors contributes to disease development.

 

About 90% of Amyotrophic Lateral Sclerosis (ALS) cases are sporadic, meaning they occur randomly without a known family history or clear risk factors. However, genetic studies suggest that inherited factors still contribute significantly, with some mutations associated with familial Amyotrophic Lateral Sclerosis also detected in sporadic cases and an estimated heritability of around 60%. Incomplete gene penetrance, overlapping conditions such as frontotemporal dementia, and environmental or unknown influences may explain why many cases appear sporadic despite underlying genetic contributions.

 

Diagnosis of Amyotrophic Lateral Sclerosis (ALS) is challenging because no single test can definitively confirm the disease. Physicians rely on clinical history, neurological examination, and diagnostic tests such as electromyography (EMG) and nerve conduction studies (NCS) to detect motor neuron dysfunction and rule out similar conditions. Neuroimaging, particularly MRI of the brain and spinal cord, is commonly used to exclude structural abnormalities that may cause similar symptoms. Additional investigations including blood and CSF tests, biomarkers like neurofilament levels, and genetic testing for mutations (e.g., C9orf72, SOD1, TDP-43, FUS, and TBK1) may support diagnosis and help differentiate ALS from other disorders.

 

There is currently no cure for Amyotrophic Lateral Sclerosis (ALS), and treatment mainly focuses on symptom management, slowing disease progression, and improving quality of life. Care is typically delivered through a multidisciplinary approach, which has been shown to enhance patient outcomes and may extend survival. Symptomatic treatments include medications for spasticity, muscle cramps, excessive saliva, and emotional instability, along with supportive therapies such as physical, occupational, and speech therapy. Nutritional support, including dietary modifications or gastrostomy tubes, may be required when swallowing becomes difficult. Non-invasive ventilation is commonly used to manage respiratory insufficiency and prolong survival. Coordinated care involving neurologists, therapists, nutritionists, pharmacists, and social workers helps address medical, functional, and psychosocial needs throughout the disease course.

 

"Amyotrophic Lateral Sclerosis (ALS) Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Amyotrophic Lateral Sclerosis (ALS) pipeline landscape is provided which includes the disease overview and Amyotrophic Lateral Sclerosis (ALS) treatment guidelines. The assessment part of the report embraces, in depth Amyotrophic Lateral Sclerosis (ALS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis (ALS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover comprehensive insights into Amyotrophic Lateral Sclerosis market trends, epidemiology, and forecasts through 2034 to drive informed decisions and strategic growth opportunities.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Amyotrophic Lateral Sclerosis (ALS) R&D. The therapies under development are focused on novel approaches to treat/improve Amyotrophic Lateral Sclerosis (ALS).

Amyotrophic Lateral Sclerosis (ALS) Emerging Drugs Chapters

This segment of the Amyotrophic Lateral Sclerosis (ALS) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Amyotrophic Lateral Sclerosis (ALS) Emerging Drugs

• NP001: Neuvivo

NP001 (sodium chlorite) is an investigational immunotherapy developed by Neuvivo for the treatment of Amyotrophic Lateral Sclerosis. It acts as a prodrug that is converted intracellularly into taurine chloramine (TauCl), which helps shift overactivated macrophages from a pro-inflammatory state to a wound-healing phenotype, thereby modulating innate immune activity. By restoring immune balance, NP001 aims to reduce chronic inflammation associated with motor neuron damage in ALS. The drug has also received Orphan Drug and Fast Track designations and is eligible for Priority Review and Accelerated Approval. The drug is currently in Preregistration Phase for the treatment of ALS.

 

• Ulefnersen: Ionis Pharmaceuticals

Ulefnersen (formerly ION-363, also known as Jacifusen) is an investigational antisense oligonucleotide (ASO) therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS) associated with mutations in the FUS gene. The therapy is designed to reduce the production of the abnormal FUS protein, which contributes to motor neuron degeneration in this form of ALS. Preclinical research has demonstrated that lowering FUS protein levels can help prevent motor neuron damage in FUS-ALS models. By targeting the underlying genetic cause, Ulefnersen aims to slow or potentially halt disease progression in affected patients. The drug is currently being evaluated in Phase III clinical development for ALS.

 

• Ibudilast: MediciNova

Ibudilast (MN-166) is an orally administered, first-in-class small-molecule drug being investigated for the treatment of amyotrophic lateral sclerosis (ALS). It acts primarily by inhibiting phosphodiesterase-4 (PDE4) and modulating inflammatory signaling pathways, including suppression of macrophage migration inhibitory factor (MIF). The drug functions as a glial cell modulator, reducing neuroinflammation by decreasing pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6, while potentially increasing anti-inflammatory IL-10 levels and antagonizing TLR4 activity. It is currently being evaluated in Phase III for the treatment of ALS.

 

• SLS-005: Seelos Therapeutics

SLS-005 is an investigational therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS). Its active component, trehalose, is a disaccharide formulated for intravenous administration and designed to cross the blood–brain barrier. The therapy works by stabilizing misfolded proteins and stimulating autophagy, a natural cellular process that clears damaged components. By enhancing this mechanism, SLS-005 may promote the removal of toxic protein aggregates in motor neurons, such as TDP-43 and SOD1, which are implicated in ALS pathology. The drug is currently being evaluated in Phase II/III clinical development for ALS.

 

• COYA 302: Coya Therapeutics

COYA 302 is an investigational biologic combination therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS). The therapy combines low-dose interleukin-2 (LD IL-2) with CTLA-4 Ig (abatacept) and is administered via subcutaneous injection. It is designed to enhance the anti-inflammatory activity of regulatory T cells (Tregs) while simultaneously suppressing activated monocytes and macrophages. Through this dual mechanism, COYA 302 aims to restore immune balance and reduce chronic neuroinflammation associated with ALS progression. The therapy is currently in Phase II clinical development for ALS.

 

• LY4256984: Eli Lilly and Company

LY4256984 is an investigational therapy being developed by Eli Lilly and Company for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. It is a targeted biologic designed to modulate neuroinflammatory pathways involved in motor neuron damage. By blocking specific immune mediators linked to neuronal injury, the therapy aims to reduce inflammation-driven neurotoxicity and help preserve motor neuron function. According to the company’s development pipeline, LY4256984 is currently being evaluated in Phase I clinical trials for ALS.

 

• VTx-001: VectorY Therapeutics

VTx-001 is an investigational gene therapy being developed by VectorY Therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS). The therapy uses an AAV-delivered vectorized antibody fragment designed to neutralize oxidized phosphatidylcholines (PC-OxPL), toxic lipid molecules believed to trigger key ALS pathologies. By targeting these upstream drivers, VTx-001 aims to prevent TDP-43 protein abnormalities and motor neuron degeneration, which are hallmark features of ALS. The therapy is currently in the preclinical stage of development.

 

• CTX2000: Celosia Therapeutics

CTX2000 is an investigational gene therapy being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS). The therapy is designed to target disease-specific molecular mechanisms involved in ALS, with the goal of protecting motor neurons and slowing neurodegeneration. By addressing underlying pathological drivers rather than only symptoms, CTX2000 aims to modify disease progression. The program is currently in the discovery stage of development.

Further product details are provided in the report……..

 

Amyotrophic Lateral Sclerosis (ALS) Therapeutic Assessment

This segment of the report provides insights about the different Amyotrophic Lateral Sclerosis (ALS) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Amyotrophic Lateral Sclerosis (ALS)

There are approx. 100+ key companies which are developing the therapies for Amyotrophic Lateral Sclerosis (ALS). The companies which have their Amyotrophic Lateral Sclerosis (ALS) drug candidates in the most advanced stage, i.e. Preregistration include, Neuvivo.

Explore comprehensive insights into Amyotrophic Lateral Sclerosis epidemiology forecast through 2034, uncover trends, drivers, and opportunities shaping future healthcare strategies.

Amyotrophic Lateral Sclerosis Phases

DelveInsight’s report covers around 110+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Amyotrophic Lateral Sclerosis Route of Administration

Amyotrophic Lateral Sclerosis (ALS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Amyotrophic Lateral Sclerosis (ALS) therapeutic drugs key players involved in developing key drugs.

Amyotrophic Lateral Sclerosis Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyotrophic Lateral Sclerosis (ALS) drugs.

Amyotrophic Lateral Sclerosis (ALS) Report Insights

• Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Amyotrophic Lateral Sclerosis (ALS) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered In The Amyotrophic Lateral Sclerosis Pipeline Report :

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Amyotrophic Lateral Sclerosis (ALS) drugs?
• How many Amyotrophic Lateral Sclerosis (ALS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Amyotrophic Lateral Sclerosis (ALS)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Amyotrophic Lateral Sclerosis (ALS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Amyotrophic Lateral Sclerosis (ALS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Neuvivo
• Ionis Pharmaceuticals
• MediciNova
• Seelos Therapeutics
• Coya Therapeutics
• Eli Lilly and Company
• VectorY Therapeutics
• Celosia Therapeutics
• Revalesio Corporation
• Rapa Therapeutics
• QurAlis Corporation
• Xalud Therapeutics, Inc
• Cellenkos
• Ractigen Therapeutics
• Alcyone Therapeutics
• NRG Therapeutics
• Neuropeutics
• Aclipse Therapeutics
• SOLA Biosciences
• Dewpoint Therapeutics

Key Products

• NP001
• Ulefnersen
• Ibudilast
• SLS-005
• COYA 302
• LY4256984
• VTx-001
• CTX2000
• RNS60
• RAPA-501
• QRL-101
• XT-150
• CK0803
• RAG-17
• EPH101
• NRG5051
• JRMS-22
• M102
• SOL 257
• TDP-43